• Revenue back to highs of over $10.0 million, up over 10% on prior quarter
• Nearly $3.0 million in shipments delivered to Germany during the quarter
• Automation and offshoring headcount reduction in Australia expected to save over $0.5 million annually

Little Green Pharma Ltd (ASX: LGP) reported revenue of $10.1 million (unaudited) for the quarter ending 30 September 2025, up over 10% on the prior quarter and consistent with the record-breaking prior corresponding period. Cash receipts were down 5% from the record high in the prior quarter but up 5% on the prior corresponding period. Revenue growth was seen across all product categories, with flower sales up nearly 15% overall, oil sales up nearly 5%, and vaporiser and edible product sales also increasing. European sales were consistent with the prior quarter, while Australian sales were up over 15%. The company delivered nearly $3.0 million in shipments to Germany during the quarter, with CherryCo sales in Germany highly encouraging. Automation and offshoring initiatives in Australia are expected to save over $0.5 million annually. The company also launched a Victorian-based distribution and 3PL service through its Health House business, completed the fit-out of a new room in Denmark for 10tpa of total active production capacity, and completed the first round of TGA consultation into Australian medicinal cannabis quality and safety. The company ended the quarter with $2.3 million in cash and $5.0 million in undrawn facilities.

Revenue of $10.1 million (unaudited) for the quarter ending 30 September 2025, up over 10% on the prior quarter. The company expects to save over $0.5 million annually from automation and offshoring initiatives.